JUVE Patent

Hamm & Wittkopp – Germany 2022

JUVE Comment

This pure patent attorney firm has a good market position in litigation for pharma and biotech companies. The strength of the practice lies in representing notable generics manufacturers, which hire the team for high-stakes cases, especially before the Federal Patent Court and EPO. The team also advises on the technical matters of infringement proceedings on the side of lawyers. Aliud, Mylan and Stada feature on the regular client list.

The practice often appears as a strawman in EPO oppositions, for example against Amgen concerning thyroid drug cinacalcet and against Bayer regarding its thrombosis blockbuster drug Xarelto.

The chemicals and biochemicals specialists frequently litigate hand-in-hand with lawyers from international firms like Bird & Bird and Taylor Wessing. The six patent attorneys at Hamm & Wittkopp focus on litigation and therefore only have a very small filing practice. They do, however, often provide clients with strategic advice and portfolio analysis.


Litigation in oppositions and infringement cases for generics manufacturers.

European set-up

Compared to rivals of a similar size, this small and flexible patent attorney outfit is well positioned for the UPC regarding pharma disputes, as it already boasts extensive litigation experience in the life sciences field. Those German cases are often part of pan-European battles between innovators and generics companies (the usual client base for Hamm & Wittkopp) over blockbuster drugs. The firm is also an attractive cooperation partner for similar firms from other European jurisdictions thanks to its specialty in chemistry and pharmaceutical patents, particularly for firms that specialise in advising generics manufacturers and have no interest in establishing their own prosecution practice in Germany.

Recommended individuals

Alexander Wittkopp, Dr. Volker Hamm (“quick, reliable, competent”, competitor)


7 patent attorneys


Prosecution, EPO oppositions as well as nullity and infringement cases related to pharma and biosimilar patents.


Litigation:Hikma Pharma (defendant) against Eli Lilly over cancer drug pemetrexed;Aliud Pharma (defendant) against Novartis over breast cancer drug everolimus; G. L. Pharma, Synthon and Alvogen (opponent) against Yeda/Teva in EPO opposition over MS drug Copaxone. Prosecution: filing and oppositions for Alfred E. Tiefenbacher. Advice: regular advice to Hikma Pharma, Stada and Mylan (all public knowledge).